body composition is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
In 1953, Major General [then Brigadier General] Kim Chum Kon, Republic of Korea Army, was made an Officer of the Legion for service 25 October 1952 – 14 February 1953. For service 10 September 1952 – 27 April 1954, Brigadier General Shim On Bong of the Republic of Korea Army For service August 1953 – March 1955, Major General Chang Kuk Chang of the Republic of Korea Army In 1957, Colonel Stig Wennerström was made an Officer of the Legion for serving as an air attaché in Washington, D.C. from 1952 to 1957. In 1958, Captain S. M. Ahsan was made an Officer of the Legion for performance of outstanding services as Naval Attache to the Embassy of Pakistan, Washington, D.C. from August 1955 to July 1956. In 1959, Major General Mian Ghulam Jilani was made an Officer of the Legion for exceptionally meritorious conduct in the performance of outstanding services to the Government of the United States, from October 1952 to June 1955. In 1960 Major General Mian Hayaud Din was made an Officer of the Legion for his role as Chief of the Pakistan Military Mission to the United States from 1955 to 1960.
To date, medical psychologists (prescribing psychologists) may prescribe psychotropic medications in Guam, Iowa, Idaho, Illinois, New Mexico, Louisiana, Colorado, Utah, Vermont, the Public Health Service, the Indian Health Service, and the United States Military. In contrast, psychiatrists are legally authorized to prescribe psychotropic medications in all states of the U.S. and in all provinces of Canada. However, psychiatrists are not usually involved in psychometric assessment. In education, clinical psychologists attend a graduate institution and have a Doctor of Philosophy (Ph.D.) or a Doctor of Psychology (Psy.D.) degree, usually following both an undergraduate and master's degree in Psychology or a related discipline. Conversely, psychiatrists complete their studies at a medical school and hold a medical degree (M.D.), Bachelor of Medicine, Bachelor of Surgery (with additional post-graduate training), or an osteopathic degree and the (D.O.) which is only available in the United States. Due to their scientist-practitioner model of training, clinical psychologists have more advanced research knowledge and skills, including advanced training in statistics, compared with standard psychiatric training.
== Common examples == When food is cooked, some of its proteins become denatured. This is why boiled eggs become hard and cooked meat becomes firm. A classic example of denaturing in proteins comes from egg whites, which are typically largely egg albumins in water. Fresh from the eggs, egg whites are transparent and liquid. Cooking the thermally unstable whites turns them opaque, forming an interconnected solid mass. The same transformation can be effected with a denaturing chemical. Pouring egg whites into a beaker of acetone will also turn egg whites translucent and solid. The skin that forms on curdled milk is another common example of denatured protein. The cold appetizer known as ceviche is prepared by chemically "cooking" raw fish and shellfish in an acidic citrus marinade, without heat.
Sources: en.wikipedia.org
Collagen alpha-1(V) chain is a protein that in humans is encoded by the COL5A1 gene. This gene encodes an alpha chain for one of the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be composed of one or more types of alpha chains. Type V collagen is found in tissues containing type I collagen and appears to regulate the assembly of heterotypic fibers composed of both type I and type V collagen. This gene product is closely related to type XI collagen and it is possible that the collagen chains of types V and XI constitute a single collagen type with tissue-specific chain combinations. Mutations in this gene are associated with Ehlers–Danlos syndrome, types I and II.
Collagen disease is a term previously used to describe systemic autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis), but now is thought to be more appropriate for diseases associated with defects in collagen, which is a component of the connective tissue. The term "collagen disease" was coined by Dr. Alvin F. Coburn in 1932, on his quest to discover streptococcal infection as the cause for rheumatic fever.
244Cm(13C,xn)257−xNo (x=4) This reaction was first studied in 1957 at the Nobel Institute in Stockholm. The scientists detected 8.5 MeV alpha particles with a half-life of 10 minutes. The activity was assigned to 251No or 253No. The results were later dismissed as background. The reaction was repeated by scientists at the LBNL in 1958 but they were unable to confirm the 8.5 MeV alpha particles. The reaction was further studied in 1967 at the LBNL and an activity assigned to 253No was measured.
Sources: en.wikipedia.org
The white shark is the sole living species in the genus Carcharodon and is one of five living species of the family Lamnidae. The other four members of this family are the mako sharks, porbeagle, and salmon shark. The family belongs to the Lamniformes, the order of mackerel sharks. The white shark first appears in the fossil record in the Pacific basin around 6–5 mya, between the late Miocene and early Pliocene. Like all sharks, the white shark's skeleton is made primarily of soft cartilage that does not preserve well. As a result, the overwhelming majority of fossils are teeth. Nevertheless, paleontologists have traced the emergence of the white shark and its immediate ancestry to a large extinct shark known as Carcharodon hastalis. This species had teeth similar to the modern white shark's, except for the cutting edges, which lacked serrations. C. hastalis occupied a similar position in the food web to modern white sharks and was probably mostly fish-eating, with some marine mammals in its diet, though its lack of serrations made it a less efficient predator of them. Around 8–6 mya, a Pacific population of C. hastalis evolved into C. hubbelli. This divergent lineage was characterized by a gradual development of serrations over the next few million years. Teeth from the same time period may exhibit significant variation in shape and their serrations, which may be indicative of persistent interbreeding with C. hastalis for at least some time. White sharks descended from C.
Romanowsky in the 1890s), it gets serially demethylated and forms all the tri-, di-, mono- and non-methyl intermediates, which are Azure B, Azure A, Azure C, and thionine, respectively. This is the basis of the basophilic part of the spectrum of Romanowski-Giemsa effect. If only synthetic Azure B and Eosin Y is used, it may serve as a standardized Giemsa stain; but, without methylene blue, the normal neutrophilic granules tend to overstain and look like toxic granules. On the other hand, if methylene blue is used it might help to give the normal look of neutrophil granules and may also enhance the staining of nucleoli and polychromatophilic RBCs (reticulocytes).
== Awards & Sponsorship == In 2011 IBA was granted multiple local innovation awards, e.g. for its Streptamer technology, which allows reversible isolation and staining of antigen-specific T cells. Additionally, a diagnostic test developed by IBA and Fassisi for veterinary diseases was chosen as one of the top five innovations by the county of Göttingen in 2015. Furthermore, the company honors young scientists and participated in research consortia as well.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.